TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21835005

Group type: EXPERIMENTAL
Intervention: Elevated red cell distribution width (RDW) > 14.5%
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Age ≥ 51 years, prior neurologic damage, immunosuppression, combination of abnormal white blood cells (WBC) and elevated RDW
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Post chest radiation state, prior neurologic damage, blood urea nitrogen (BUN) > 10.7 mmol/L, RDW > 14.5%
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Increased RDW regardless of white blood cell count
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Elevated RDW
Number of subjects: 637
Study: 21835825

Group type: EXPERIMENTAL
Intervention: ASA404 (1800 mg/m²) plus docetaxel (75 mg/m²)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ASA404 (1800 mg/m²) plus docetaxel (60 mg/m²)
Number of subjects: 9
Study: 21836106

Group type: EXPERIMENTAL
Intervention: Habitual short sleep (average of 1.5 h less sleep per night)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual sleep duration >6 h/day
Number of subjects: 47
Study: 21836107

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessment in youth with type 2 diabetes
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Comparison of depressive symptoms in older girls vs older boys
Number of subjects: 704

Group type: COMPARATOR
Intervention: Comparison of depressive symptoms in youth with type 2 diabetes vs healthy adolescents
Number of subjects: 704

Group type: COMPARATOR
Intervention: Comparison of depressive symptoms in youth with type 2 diabetes vs teens with type 1 diabetes
Number of subjects: 704
Study: 21836143

Group type: EXPERIMENTAL
Intervention: Urine IL-18
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Clinical prediction model for AKI
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Urine IL-18 and Plasma NGAL
Number of subjects: 1219
Study: 21836147

Group type: EXPERIMENTAL
Intervention: Urine IL-18
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Urine IL-18 and Urine NGAL
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 311
Study: 21838412

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg orally once daily for days 1 to 3; 0.5 mg twice daily for days 4 to 7; 1 mg twice daily for the remainder of a 12-week treatment period)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 330
Study: 21838881

Group type: EXPERIMENTAL
Intervention: Increased plasma osteoprotegerin (OPG) levels in patients with carotid arterial disease
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Increased plasma osteoprotegerin (OPG) levels in patients with peripheral arterial disease
Number of subjects: 305

Group type: COMPARATOR
Intervention: Myocardial ischemia
Number of subjects: 305
Study: 21839411

Group type: EXPERIMENTAL
Intervention: Preference-based measure derived from EORTC QLQ-C30
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Valuation study using time trade-off
Number of subjects: 655
Study: 21839981

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: BMI quintiles
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Sex (Women)
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Sex by BMI interaction
Number of subjects: 1487
Study: 21840522

Group type: EXPERIMENTAL
Intervention: NRS 4-6
Number of subjects: 10434

Group type: COMPARATOR
Intervention: NRS scores interpretation by professionals
Number of subjects: 10434

Group type: COMPARATOR
Intervention: NRS scores interpretation by Acute Pain Nurses
Number of subjects: 10434

Group type: COMPARATOR
Intervention: Guidelines for analgesic treatment
Number of subjects: 10434
Study: 21840837

Group type: EXPERIMENTAL
Intervention: Mobilyze! intervention
Number of subjects: 8
Study: 21841163

Group type: EXPERIMENTAL
Intervention: Clofarabine combined with myeloablative doses of busulfan
Number of subjects: 46
Study: 21844482

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 10
Study: 21845241

Group type: EXPERIMENTAL
Intervention: Collagen barrier membrane
Number of subjects: 10
Study: 21846339

Group type: EXPERIMENTAL
Intervention: Severe Hepatic Steatosis (HS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IGF-I zSDS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IGFBP-1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IGF-I/IGFBP-3 ratio
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FM%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SLD
Number of subjects: 48
Study: 21846371

Group type: EXPERIMENTAL
Intervention: 3 g/d reduced viscosity barley β-glucan (BBG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6 g/d reduced viscosity barley β-glucan (BBG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 21846636

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (TIV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combinations of LAIV and TIV
Number of subjects: 100
Study: 21849262

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 3000000
Study: 21849481

Group type: EXPERIMENTAL
Intervention: Intervention therapy for life-threatening symptoms (n = 29/38; 76%)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Risk groups based on clinical findings
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Overall occurrence of acute myeloid leukemia (AML)
Number of subjects: 135
Study: 21849486

Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, administered after prior conditioning with cyclophosphamide.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, administered to a patient with relapsed ALL.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, with prior cyclophosphamide administration.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, retrieved 8 days after infusion.
Number of subjects: 10
Study: 21850464

Group type: EXPERIMENTAL
Intervention: Bortezomib and temozolomide (MTDs: 1.3 mg/m² for bortezomib and 200 mg/m² for temozolomide)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bortezomib (with HEIAs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bortezomib (without HEIAs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bortezomib and temozolomide (in patients not taking HEIAs)
Number of subjects: 25
Study: 21851846

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (SGA) treatment
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Genetic variants predictive of cardiovascular risk factors
Number of subjects: 924
Study: 21852114

Group type: EXPERIMENTAL
Intervention: PF-03814735 (80mg QD on Schedule A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PF-03814735 (50mg QD on Schedule B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PF-03814735
Number of subjects: 57
Study: 21852284

Group type: EXPERIMENTAL
Intervention: Paternal Longevity (living to at least 80 years)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Maternal Longevity (living to at least 80 years)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Premature Death of Father (death at age < 50 years)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Premature Death of Mother (death at age < 50 years)
Number of subjects: 4000
Study: 21852295

Group type: EXPERIMENTAL
Intervention: V/Q SPECT scan
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: V/Q SPECT scan combined with clinical probability
Number of subjects: 321
Study: 21852311

Group type: EXPERIMENTAL
Intervention: CRT-Ds with Home Monitoring
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Positive predictor finding
Number of subjects: 377
Study: 21852337

Group type: EXPERIMENTAL
Intervention: Sniffer dogs applied to exhalation samples from lung cancer patients
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sniffer dogs applied to exhalation samples from healthy individuals and COPD patients
Number of subjects: 220
Study: 21854271

Group type: EXPERIMENTAL
Intervention: Monogamous men (self-reported)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Men with committed relationships and casual partners
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Monogamous men
Number of subjects: 360
Study: 21854593

Group type: EXPERIMENTAL
Intervention: Extended antibiotic treatment with clindamycin and metronidazole plus vaginal gelatine capsules containing different strains of lactobacilli (109 freeze-dried bacteria per capsule)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Change of partner during follow-up
Number of subjects: 63
Study: 21855974

Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index (FSFI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Endometrial (FACT-En)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Center for Epidemiology Studies Depression scale (CES-D)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Menopausal Rating Scale (MRS)
Number of subjects: 72
Study: 21856678

Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Number of subjects: 31
Study: 21856841

Group type: EXPERIMENTAL
Intervention: Groundwater spiked with Norwalk virus; stored at room temperature in the dark for 61 days.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Groundwater spiked with Norwalk virus; stored for 1,266 days.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Purified Norwalk virus RNA extracted from virions; stored in groundwater, tap water, and reagent-grade water.
Number of subjects: 13
Study: 21856867

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 207
Study: 21857263

Group type: EXPERIMENTAL
Intervention: 2009-2010 TIV containing B/Brisbane/60/08(Victoria) antigen
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 2010-2011 TIV containing B/Brisbane/60/08(Victoria) antigen
Number of subjects: 92
Study: 21857286

Group type: EXPERIMENTAL
Intervention: Didanosine, lamivudine, efavirenz (once-daily administration)
Number of subjects: 51
Study: 21857490

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg once daily and Raltegravir (RAL) 400 mg twice daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) plus Raltegravir (RAL)
Number of subjects: 112
Study: 21857793

Group type: EXPERIMENTAL
Intervention: Intervention (school-based curriculum to delay sexual initiation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study: 21858552

Group type: EXPERIMENTAL
Intervention: Sorafenib followed by Sunitinib (SOR-SUN)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sunitinib followed by Sorafenib (SUN-SOR)
Number of subjects: 33
Study: 21859168

Group type: EXPERIMENTAL
Intervention: Hangover insensitivity at Time 1
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hangover severity at Time 1
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hangover sensitivity at Time 1
Number of subjects: 134
Study: 21859692

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg or 2 mg/kg (≤40 kg) subcutaneously every 8 weeks for up to 2 years
Number of subjects: 166
Study: 21859696

Group type: EXPERIMENTAL
Intervention: Adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 340
Study: 21860025

Group type: EXPERIMENTAL
Intervention: GEP70 risk stratification
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GEP15 risk stratification
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FISH based risk stratification
Number of subjects: 45
Study: 21860347

Group type: EXPERIMENTAL
Intervention: Raltegravir and Truvada for 52 weeks
Number of subjects: 16
Study: 21860633

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 1-month depot administered intramuscularly every 28 days.
Number of subjects: 55
Study: 21860975

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 18
Study: 21861537

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular weight heparin/warfarin
Number of subjects: 0
Study: 21862407

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice a day
Number of subjects: 91
Study: 21865328

Group type: EXPERIMENTAL
Intervention: Higher body weight-adjusted abdominal fat mass (AFM)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Total fat mass (TFM)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Body weight-adjusted AFM increase
Number of subjects: 629
Study: 21865346

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once-daily dosing
Number of subjects: 288
Study: 21865361

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Thigh fat
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: VAT tertile grouping
Number of subjects: 115
Study: 21865561

Group type: EXPERIMENTAL
Intervention: TCN2 67AG genotype
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: TCN2 67GG genotype
Number of subjects: 2411

Group type: COMPARATOR
Intervention: TCN2 67AA genotype
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67AG in strata of 776CC
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67GG in strata of 776CC
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67AG in strata of 776CG
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67GG in strata of 776CG
Number of subjects: 2411
Study: 21867401

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) 1.3 g administered three-times daily for up to 5 days per menstrual cycle (maximum of 15 doses)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA)
Number of subjects: 723
Study: 21867539

Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional mental health promotion intervention (6-month program with regular home visits and monthly case conferences)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional mental health promotion intervention
Number of subjects: 250
Study: 21867843

Group type: EXPERIMENTAL
Intervention: Midregion proadrenomedullin (MR-proADM)
Number of subjects: 1641
Study: 21868014

Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for COQ2 (rs4693570)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for ATP2B1 (rs17381194)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for DMPK (rs672348)
Number of subjects: 793
Study: 21868463

Group type: EXPERIMENTAL
Intervention: Tracheal stent placement
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Operative tracheobronchoplasty (TBP)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Measured FEV(1) and exercise capacity (6-min walk test)
Number of subjects: 103
Study: 21868572

Group type: EXPERIMENTAL
Intervention: Fixed dose of donor T cells (2 × 10(8)/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients without disease at HSCT
Number of subjects: 27
Study: 21868778

Group type: EXPERIMENTAL
Intervention: Low glucose suspend (LGS) feature of the Paradigm Veo insulin pump
Number of subjects: 31
Study: 21869687

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d for 1 year
Number of subjects: 599
Study: 21871057

Group type: EXPERIMENTAL
Intervention: Walnut oil (0.5 mg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human sera (10%, v:v) from walnut feeding study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intervention (walnut intake)
Number of subjects: 0
Study: 21873548

Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients in adult AML
Number of subjects: 527

Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients in adult AML achieving complete remission
Number of subjects: 527

Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients with normal cytogenetics
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: SNP rs11554137 positivity in adult AML
Number of subjects: 527
Study: 21874061

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study: 21874317

Group type: EXPERIMENTAL
Intervention: Oral metronomic cyclophosphamide (CTX) 65 mg/m² daily on days 1-14 plus capecitabine 1,000 mg/m² twice daily on days 1-14, repeated every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Number of subjects: 68
Study: 21875676

Group type: EXPERIMENTAL
Intervention: Symptomatic hip osteoarthritis
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Symptomatic knee osteoarthritis
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Standardized prevalence of hip OA
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Standardized prevalence of knee OA
Number of subjects: 1010
Study: 21876119

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy at maximum tolerated dose (MTD)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 174
Study: 21877169

Group type: EXPERIMENTAL
Intervention: Eculizumab, 600 mg every 2 weeks
Number of subjects: 1

Group type: COMPARATOR
Intervention: Plasma exchange (initial treatment)
Number of subjects: 1
Study: 21877508

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate spray 0.05% in the morning and calcitriol ointment 3 microg/g in the evening for up to 4 weeks
Number of subjects: 0
Study: 21877895

Group type: EXPERIMENTAL
Intervention: LC-MS/MS assay for detecting keratan sulfate-derived disaccharides in urine and plasma
Number of subjects: 168
Study: 21880642

Group type: EXPERIMENTAL
Intervention: High pentraxin 3 levels on day 0
Number of subjects: 100
Study: 21880803

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention (nutrition education, exercise training, behavior therapy)
Number of subjects: 59
Study: 21883440

Group type: EXPERIMENTAL
Intervention: Moderate psychological stress (Trier Social Stress Test) in the postprandial state (75 min after a standard meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate psychological stress (Trier Social Stress Test) in the fasting state
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control day (no stress)
Number of subjects: 30
Study: 21884592

Group type: EXPERIMENTAL
Intervention: Asymmetric tumor necrosis factor (TNF)-induced knee arthritis in TNF-Tg mice
Number of subjects: 0
Study: 21884947

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Transplant-free survival
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Survival free of heart failure hospitalization
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: LVEF
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter at presentation
Number of subjects: 373
Study: 21884952

Group type: EXPERIMENTAL
Intervention: Strain-encoded magnetic resonance imaging (SENC) during high-dose dobutamine stress cardiac magnetic resonance imaging (DS-MRI)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Resting and inducible wall motion abnormalities (WMA)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Visual SENC or quantitative strain rate reserve
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: SENC in a subset of patients who underwent coronary angiography (n = 175)
Number of subjects: 320
Study: 21885599

Group type: EXPERIMENTAL
Intervention: Cultured red blood cells (cRBCs)
Number of subjects: 1
Study: 21885601

Group type: EXPERIMENTAL
Intervention: Management approaches for ALPS and its associated cytopenias
Number of subjects: 500
Study: 21885723

Group type: EXPERIMENTAL
Intervention: Exercise at high altitude
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise-induced pulmonary hypertension
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 15
Study: 21885725

Group type: EXPERIMENTAL
Intervention: Severity of asthma (SOA) score
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Asthma control test (ACT)
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Work productivity and impairment index-asthma (WPAI-A)
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: FEV(1) % predicted
Number of subjects: 2878
Study: 21885890

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for physical activity assessment
Number of subjects: 491
Study: 21885891

Group type: EXPERIMENTAL
Intervention: ≥ 7500 steps/day
Number of subjects: 985

Group type: COMPARATOR
Intervention: < 7500 steps/day
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Greater steps/day (combined for men and women)
Number of subjects: 985
Study: 21887501

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 0.7-2.0 mg/m2
Number of subjects: 15
Study: 21888637

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m² IV on days 1 and 8) and capecitabine (900 mg/m² orally twice a day on days 1-14)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and capecitabine
Number of subjects: 32
Study: 21889330

Group type: EXPERIMENTAL
Intervention: Axitinib (5mg twice daily)
Number of subjects: 64